Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
The Candel Therapeutics, Inc. (CADL) news page on Stock Titan aggregates company-issued updates, press releases, and related coverage focused on its multimodal viral immunotherapy programs in oncology. Candel describes itself as a clinical-stage biopharmaceutical company developing off-the-shelf biological immunotherapies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, with lead candidates CAN-2409 and CAN-3110 in solid tumors.
Visitors to this page can follow announcements about clinical trial progress, including pivotal and phase 2 studies of CAN-2409 in intermediate-to-high-risk localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC), as well as phase 1b data for CAN-3110 in recurrent high-grade glioma. Candel’s releases also highlight regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug Designation granted by the U.S. Food and Drug Administration for specific indications.
News items frequently cover scientific presentations at major conferences, including ASTRO, ASCO, and the Society for Immunotherapy of Cancer (SITC), where Candel discusses subgroup analyses, biomarker findings, and multi-omics data related to its viral immunotherapy approach. Additional updates describe financing transactions, such as equity offerings and a term loan facility, as well as corporate developments like research advisory board appointments and investor conference participation.
By reviewing the CADL news feed, investors and researchers can see how Candel communicates the evolution of its CAN-2409 and CAN-3110 programs, the role of the enLIGHTEN™ Discovery Platform, and key milestones disclosed in its own press releases and referenced in SEC filings. Bookmark this page to access a centralized view of Candel’s publicly released information on its oncology-focused pipeline and corporate activities.
Candel Therapeutics, Inc. (Nasdaq: CADL) reported its Q2 2022 financial results, revealing a net loss of $4.1 million, a significant decrease from $17.1 million in Q2 2021. The company maintains a strong cash position of $86.8 million, sufficient to fund operations into Q1 2024. Candel announced a promising 87.5% disease control rate from its phase 2 clinical trial of CAN-2409 in NSCLC at ASCO 2022. Upcoming milestones include phase 3 trials for high-grade glioma and updates on their enLIGHTEN™ Discovery Platform.
Candel Therapeutics, Inc. (Nasdaq: CADL) announced the appointment of three new board members, Gary Nabel, Joseph C. Papa, and Renee Gaeta, effective August 8, 2022. Their extensive experience in biopharmaceuticals and finance is expected to bolster Candel's strategies in oncolytic viral immunotherapies for cancer treatment. The new directors replace outgoing members, maintaining the board's nine-member structure. Candel aims to leverage this leadership change to enhance its growth and innovation in the cancer treatment space.
Candel Therapeutics reported promising findings from its Phase 2 clinical trial of CAN-2409 in patients with advanced non-small cell lung cancer (NSCLC) at the ASCO Annual Meeting.
The trial demonstrated a 87.5% disease control rate in patients previously progressing on anti-PD-1 therapy, with 62.5% showing durable stabilization. A 15% partial response rate was observed, along with tumor regression in both injected and uninjected lesions. The treatment was well tolerated, highlighting CAN-2409's potential as a viable option for NSCLC patients lacking effective alternatives.
Candel Therapeutics, a late clinical-stage biopharmaceutical company focused on oncolytic viral immunotherapies, announced that CEO Paul Peter Tak will present at H.C. Wainwright’s Annual Global Investment Conference.
Date: May 24, 2022, Time: 7:00 am ET for on-demand viewing. Candel's leading candidates include CAN-2409 and CAN-3110, designed to induce immune responses against cancer. For more details, visit Candel Therapeutics’ website.
Candel Therapeutics (Nasdaq: CADL) reported its Q1 2022 financial results and outlined key advancements in oncolytic viral immunotherapy for cancer. The company strengthened its cash position with a $20 million debt financing and reported cash equivalents of $94.3 million as of March 31, 2022. Research and development expenses rose to $5.4 million, reflecting increased clinical trial activities. Notably, the net loss decreased to $874,000 compared to $4.5 million in Q1 2021. Candel is set to present pivotal clinical data at the upcoming ASCO Annual Meeting in June 2022.
Candel Therapeutics, Inc. (Nasdaq: CADL) announced the acceptance of an abstract for presentation at the ASCO Annual Meeting 2022, scheduled for June 3-7 at McCormick Place, Chicago. The abstract will present data from a phase 2 clinical trial on CAN-2409 and valacyclovir in combination with anti-PD-1/PD-L1 agents for treating stage III/IV NSCLC patients. Key details include:
- Abstract Title: First report of safety/tolerability and preliminary antitumor activity of CAN-2409
- Presenter: Charu Aggarwal
- Date: June 6, 2022
- Abstract Number: 9037
Candel Therapeutics (CADL) reported a strong cash position of $82.6 million as of December 31, 2021, up from $35.1 million in 2020, bolstered by a successful IPO. Despite a net loss of $36.1 million for the year, the company plans to present key clinical trial data in 2022, seeking to advance its oncolytic viral immunotherapies for various cancers. Operating expenses increased to $25.9 million, driven by R&D and administrative costs linked to its growth strategy. Candel is positioned for critical milestones with upcoming data readouts expected in mid-2022.
Candel Therapeutics (Nasdaq: CADL) has appointed Dr. Seshu Tyagarajan as the Chief Technical and Development Officer. Tyagarajan brings over 20 years of experience from Novartis, where she led CGT manufacturing strategies, including the BLA submission for Kymriah, the first FDA-approved CAR-T therapy. Her expertise in biologics manufacturing is expected to enhance Candel’s development efforts for oncolytic viral immunotherapy, which targets solid tumors. The company aims to leverage her insights to elevate its technical operations.
Candel Therapeutics, Inc. (Nasdaq: CADL) has secured a $25 million loan from Silicon Valley Bank, with $20 million available immediately and up to $5 million contingent on specific milestones. This financing extends the company's cash runway into Q4 2023, providing operational flexibility ahead of key clinical trials, including CAN-2409 and CAN-3110. CEO Paul Peter Tak highlights the attractive, non-dilutive terms of the loan as beneficial for upcoming data release and trial initiation, crucial for the company's oncolytic viral immunotherapy programs.
Candel Therapeutics, Inc. (Nasdaq: CADL) has appointed Francesca Barone, M.D., Ph.D., as its new Chief Scientific Officer. With over 20 years of expertise in immunology and drug development, Dr. Barone previously served as Candel's Vice President, Head of Research. She has substantial experience from her roles at Kintai Therapeutics and Senda Biosciences. Dr. Barone expressed optimism about the company's investigational immunotherapies aimed at treating cancer, emphasizing their unique ability to induce strong immune responses. This leadership change aims to enhance Candel's clinical development efforts.